 |
[Apha Biz=(Chicago) Reporter Paul Lee] Samsung Bioepis said nothing has been decided on whether to take over Biogen's biosimilar division in the U.S.
According to related industries on the 2nd, Samsung Bioepis is currently considering acquiring the Biogen biosimilar division. However, an official at Samsung Bioepis said, "There has been no final decision so far regarding the acquisition of Biogen's biosimilar division."
"Samsung Bioepis is considering various strategies to secure global biosimilar business capabilities, and is currently focusing on R&D on competitive pipelines and expanding sales of existing products," he added.
In the meantime, a task force (TF) was formed to acquire the business unit Or some reports that the due diligence has been completed are not true.
AlphaBIZ 폴 리(hoondork1977@alphabiz.co.kr)
